Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?
Research output: Contribution to journal › Review › Research › peer-review
Standard
Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists : Could this work and how? / Smits, Mark M.; Holst, Jens J.
In: Diabetes/Metabolism Research and Reviews, Vol. 39, No. 8, e3699, 2023.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists
T2 - Could this work and how?
AU - Smits, Mark M.
AU - Holst, Jens J.
N1 - Publisher Copyright: © 2023 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.
PY - 2023
Y1 - 2023
N2 - In recent years, we have witnessed the many beneficial effects of glucagon-like peptide (GLP)-1 receptor agonists, including the reduction in cardiovascular risk in patients with type 2 diabetes, and the reduction of body weight in those with obesity. Increasing evidence suggests that these agents differ considerably from endogenous GLP-1 when it comes to their routes of action, although their clinical effects appear to be the same. Given the limitations of the GLP-1 receptor agonists, could it be useful to develop agents which stimulate GLP-1 release? Here we will discuss the differences and similarities between GLP-1 receptor agonists and endogenous GLP-1, and will detail how endogenous GLP-1—when stimulated appropriately—could have clinically relevant effects.
AB - In recent years, we have witnessed the many beneficial effects of glucagon-like peptide (GLP)-1 receptor agonists, including the reduction in cardiovascular risk in patients with type 2 diabetes, and the reduction of body weight in those with obesity. Increasing evidence suggests that these agents differ considerably from endogenous GLP-1 when it comes to their routes of action, although their clinical effects appear to be the same. Given the limitations of the GLP-1 receptor agonists, could it be useful to develop agents which stimulate GLP-1 release? Here we will discuss the differences and similarities between GLP-1 receptor agonists and endogenous GLP-1, and will detail how endogenous GLP-1—when stimulated appropriately—could have clinically relevant effects.
KW - diabetes
KW - glucagon-like peptide-1
KW - gut hormone
KW - obesity
U2 - 10.1002/dmrr.3699
DO - 10.1002/dmrr.3699
M3 - Review
C2 - 37485788
AN - SCOPUS:85165442315
VL - 39
JO - Diabetes/Metabolism Research and Reviews
JF - Diabetes/Metabolism Research and Reviews
SN - 1520-7552
IS - 8
M1 - e3699
ER -
ID: 360860975